francescalongo retweeted
Rare Cancers Europe & JARC at the @EMA_News today discussing the role #ERNs have to play in licensing process of new #rarecancer agents @eurordis, @accrf_org, @SIOPEurope, @cancereu, @ERN_EURACAN, @casali_pg, @theIBTA @myESMO
francescalongo retweeted
2nd #ESORareCancers now ending. Done by ESO & ESMO in collaboration with EURACAN & JARC. All 10 families of rare adult solid cancers discussed on a multidisciplinary basis. A patient advocates’ course held in parallel. Let’s think together then how to shape 3rd edition in 2018.
francescalongo retweeted
This weekend our trustee @torijanes was in Milan at #ESORareCancers @_rarecancer to talk about patient advocacy @GISTSupportUK and @PAWSGIST
francescalongo retweeted
@myESMO Magnitude of Clinical Scale Munich Workshop Science for Advocates #patientsinvolved
francescalongo retweeted
Greetings from Munich! E de Vries talking about ESMO Magnitude of Clinical Benefit Scale - Science for #PatientAdvocates workshop
francescalongo retweeted
The ESMO Science for #PatientAdvocates workshop kicking off in Munich, 'Why advocates should care about science' @BettinaRyll
francescalongo retweeted
The @ESMO_Open staff wishes you all the most happy holiday season and all the best for 2017! @M_Preusser @cczielinski
francescalongo retweeted
Late stage diagnosis one of several contributors to global #cancercare disparities R Stahel @myESMO
francescalongo retweeted
#Cancer Pat Advocacy Netwks WS: @BettinaRyll welcomes patients keen to drive clinical res bit.ly/23Pg4FE
francescalongo retweeted
24/3 MEP Alojz Peterle, Rare Cancers Europe & ESMO event: European Reference Networks #rareCSM @myESMO @lojzepeterle bit.ly/1E8g5ah
francescalongo retweeted
Removing Eve’s rare cancer drug also removes hope of finding a cure. #100000voices needed: bit.ly/100000voices
francescalongo retweeted
#RareDisease Patient Advocates: Follow These 25 Twitter Accounts | Thank you @eurordis @RareConnect #FF :-) moderators.rareconnect.org/s…
francescalongo retweeted
Our paper on methodological recommendations for clinical studies in #rarecancers now published in Annals of Oncology ow.ly/CeL9I
francescalongo retweeted
RT @_rarecancer: A call for new methodologies to be applied to #clinicaltrials in #rarecancers bit.ly/1pry4iD
francescalongo retweeted
1 in 5 cancers are #rarecancers #esmo2014 addresses implications for regulatory agenda, clinical decision-making
francescalongo retweeted
In a nutshell, methodological challenges: few patients, low level of data, standard of care unclear J Bogaerts #rarecancers
francescalongo retweeted
ESMO and patient orgs agree on joint policy action to ensure patient access for future conf #ESMO14 #advocatesIN
